The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600EInhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells | Zendy

Ruixin Liu | Zendy; Dingxie Liu | Zendy; Mingzhao Xing | Zendy

Open Access

The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAF^V600EInhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells

Author(s) -

Ruixin Liu,

Dingxie Liu,

Mingzhao Xing

Publication year - 2011

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-1054

Subject(s) - cancer research , protein kinase b , thyroid cancer , papillary thyroid cancer , mapk/erk pathway , medicine , pi3k/akt/mtor pathway , mek inhibitor , cancer , kinase , pharmacology , chemistry , signal transduction , biochemistry

The purpose of the study was to explore optimal combinations of currently actively developed drugs for dually targeting the Ras → Raf → MAPK kinase (MEK) → MAPK/ERK (MAPK) and the phosphatidylinositol 3-kinase/Akt pathways as effective treatments for thyroid cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research